Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. It uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The Company’s SMDCs actively target receptors that are over-expressed on diseased cells relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.


Type
Public
HQ
West Lafayette, US
Founded
1995
Size (employees)
76 (est)-2%
Endocyte was founded in 1995 and is headquartered in West Lafayette, US

Key People at Endocyte

Mike A. Sherman

Mike A. Sherman

President & CEO

Endocyte Office Locations

Endocyte has offices in West Lafayette and Indianapolis
West Lafayette, US (HQ)
3000 Kent Avenue
Indianapolis, US
8910 Purdue Rd, Suite 250

Endocyte Data and Metrics

Endocyte Financial Metrics

Endocyte's revenue was reported to be $12.5 k in Q1, 2017
USD

Revenue (Q1, 2017)

12.5 k

Net income (Q1, 2017)

(11.5 m)

EBIT (Q1, 2017)

(11.7 m)

Market capitalization (21-Jul-2017)

60.7 m

Cash (31-Dec-2016)

31.2 m
Endocyte's current market capitalization is $60.7 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

64.9 m70.4 m70 k70 k

Revenue growth, %

8%(100%)

R&D expense

27.5 m

General and administrative expense

17.3 m

Operating expense total

83.2 m65.3 m42 m44.8 m

EBIT

(18.3 m)5 m(42 m)(44.7 m)

EBIT margin, %

(28%)7%(59961%)(63886%)

Interest expense

2.5 k1.2 k

Interest income

465.5 k578.6 k

Net Income

(18 m)5.5 m(41.3 m)(43.9 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

12.5 k12.5 k12.5 k32.5 k12.5 k

R&D expense

19 m5.7 m6.6 m6.7 m6.6 m6.5 m6.8 m6 m8 m

General and administrative expense

8 m4 m4.4 m4.1 m3.8 m3.8 m7.4 m3 m3.7 m

Operating expense total

27 m9.7 m11 m10.8 m10.4 m10.4 m14.2 m9 m11.7 m

EBIT

22.2 m(5.8 m)(11 m)(10.8 m)(10.3 m)(10.3 m)(14.2 m)(8.9 m)(11.7 m)

EBIT margin, %

(87718%)(82710%)(113355%)(27507%)(93818%)

Interest expense

(431)(252)

Interest income

169 k161.3 k

Net Income

22.4 m(5.7 m)(10.9 m)(10.6 m)(10 m)(10.2 m)(14 m)(8.7 m)(11.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

52.8 m45.5 m15.4 m31.2 m

Current Assets

133.3 m127 m174.9 m140.3 m

PP&E

3.8 m4 m3.4 m3.2 m

Total Assets

162.9 m212.8 m178.4 m143.5 m

Accounts Payable

5.4 m1.2 m1.3 m1.4 m

Current Liabilities

73.7 m6.9 m6.2 m5.6 m

Total Liabilities

6.3 m

Additional Paid-in Capital

262.1 m373.6 m381.1 m390.8 m

Retained Earnings

(173.9 m)(168.5 m)(209.7 m)(253.6 m)

Total Equity

205 m171.3 m137.1 m

Financial Leverage

1 x1 x1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Cash

31.6 m48.6 m29.2 m28 m31 m40.2 m26.6 m34.7 m

Current Assets

128.7 m134.3 m162.2 m175 m173.7 m164.8 m155.8 m148.5 m

PP&E

4.2 m4.1 m3.8 m3.7 m3.6 m3.6 m3.5 m3.4 m

Total Assets

230.9 m221 m202.6 m194 m185.6 m168.5 m159.4 m152 m

Accounts Payable

3.5 m1.1 m1.6 m1.5 m956.9 k1.2 m1.4 m1.5 m

Current Liabilities

15.3 m9.3 m5.5 m5.5 m5.4 m4.3 m4.5 m4.6 m

Additional Paid-in Capital

369.4 m371.2 m375.5 m377.6 m379.2 m383.2 m387.8 m389.1 m

Retained Earnings

(154.7 m)(160.4 m)(179.3 m)(189.9 m)(199.9 m)(219.9 m)(233.9 m)(242.6 m)

Total Equity

210.8 m196.2 m187.6 m179.4 m163.4 m154 m146.6 m

Financial Leverage

1 x1 x1 x1 x1 x1 x1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18 m)5.5 m(41.3 m)(43.9 m)

Depreciation and Amortization

674.7 k857.1 k886.7 k

Accounts Payable

(386.2 k)(3.7 m)(60.7 k)1.4 m

Cash From Operating Activities

(51.1 m)(42.2 m)(32.2 m)

Purchases of PP&E

(827.8 k)(1.5 m)(341.6 k)

Cash From Investing Activities

69.3 m(68.6 m)1.5 m

Cash From Financing Activities

644.9 k103.5 m627 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

22.4 m(5.7 m)(10.9 m)(10.6 m)(10 m)(10.2 m)(14 m)(8.7 m)(11.5 m)

Accounts Payable

3.5 m1.1 m1.6 m1.5 m956.9 k1.2 m1.4 m1.5 m1.5 m
USDY, 2017

Revenue/Employee

164.5

Endocyte Market Value History

Endocyte Company Life and Culture

You may also be interested in